

# ASH Guidelines on Prevention and Treatment of VTE in Patients with Cancer Supplement 3: Disclosure of Interest Forms of Researchers who Contributed to the Guidelines

Elie Akl

Maddalena Barba

Maram Hakoum

Lara Kahale

Charbel Matar

Francesca Sperati

Irene Terrenato

Ibrahim Tsolakian

Victor Yosunico



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**X No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I was an author on five guidelines on the topic of anticoagulation for venous thromboembolic disease published by the American College of Chest Physicians in 2012:

1. Guyatt G, **Akl EA**, Crowther M, Schünemann HJ, Gutterman D, Zelman-Lewis S. Executive Summary. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):7S–47S [Link](#)

2. Kahn SR, Lim W, Dunn A, Cushman M, Dentali F, **Akl EA**, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad HM. Prevention of VTE in Nonsurgical Patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guideline. CHEST 2012; 141(2)(Suppl):e195S–e226S [Link](#)
3. Kearon, Clive; **Akl, Elie**; Comerota, Anthony; Prandoni, Paolo; Bounameaux, Henri; Goldhaber, Samuel; Nelson, Michael; Wells, Philip; Gould, Michael; Dentali, Francesco; Crowther, Mark; Kahn, Susan Antithrombotic Therapy for Venous Thromboembolic Disease: ACCP Evidence-Based Clinical Practice Guidelines (Ninth Edition). CHEST 2012; 141(2)(Suppl):e419S–e494S [Link](#)
4. Lansberg MG, O'Donnell MJ, Nguyen-Huynh MN, Khatri P, Lang E, Schwartz N, Sonnenberg FA, Schulman S, Vandvik PO, Spencer F, Alonso-Coello A, Guyatt G, **Akl EA**. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: ACCP Evidence-Based Clinical Practice Guidelines (Ninth Edition). CHEST 2012; 141(2)(Suppl):e601S–e636S [Link](#)
5. Vandvik PO, Lincoff AM, Gore JM, Gutterman D, Sonnenberg FA, Alonso-Coello P, **Akl EA**, Lansberg M, Guyatt G, Spencer FA. Primary and Secondary Prevention of Cardiovascular Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e637S–e668S [Link](#)

I was an author on one guideline on the topic of anticoagulation for venous thromboembolic disease published by the American College of Chest Physicians in 2016:

1. Kearon C, **Akl EA**, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-52. Epub 2016 Jan 7. [Link](#)

I was an author on two guidelines on the topic of anticoagulation for venous thromboembolic disease published by the Ministry of Health of the Kingdom of Saudi Arabia:

1. Al-Hameed FM, Al-Dorzi HM, Al-Momen AM, Algahtani FH, Al-Zahrani HA, Al-Saleh KA, Al-Sheef MA, Owaidah TM, Alhazzani W, Neumann I, Wiercioch W, Brozek J, Schunemann H, **Akl EA**. The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management. Saudi Med J. 2015 Aug;36(8):1004-10. [Link](#)
2. Al-Hameed F, Al-Dorzi HM, AlMomen A, Algahtani F, AlZahrani H, AlSaleh K, AlSheef M, Owaidah T, Alhazzani W, Neumann I, Wiercioch W, Brozek J, Schünemann H, **Akl EA**. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline. Ann Saudi Med. 2015 Mar-Apr;35(2):95-106. [Link](#)

## Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

I am an author on six Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000. My role was the principal investigator.

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer

Elie A Akl , Lara A Kahale , Francesca Sperati , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Maddalena Barba , Elena V Sempos , Paola Muti , Deborah Cook and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: June 2014

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation

Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosunico , Maddalena Barba , Francesca Sperati and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: July 2014

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

Elie A Akl , Lara A Kahale , Ignacio Neumann , Maddalena Barba , Francesca Sperati , Irene Terrenato , Paola Muti and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: June 2014

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer  
Elie A Akl , Lara A Kahale , Maddalena Barba , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Francesca Sperati , Paola Muti and Holger Schünemann.

Cochrane Database of Systematic Reviews

Online Publication Date: July 2014

Anticoagulation for people with cancer and central venous catheters

Elie A Akl , Elie P Ramly , Lara A Kahale , Victor E D Yosuíco , Maddalena Barba , Francesca Sperati , Deborah Cook and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: October 2014

Parenteral anticoagulation in ambulatory patients with cancer

Elie A Akl , Lara A Kahale , Rami A Ballout , Maddalena Barba , Victor E D Yosuíco , Frederiek F van Doormaal , Saskia Middeldorp , Andrew Bryant and Holger Schünemann.

Cochrane Database of Systematic Reviews

Online Publication Date: December 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

No

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know



**X No**

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

I would expect the support I would normally expect

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**X No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

General Internist

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

**X Yes**

If yes, please explain:

Pharmacological or mechanical thromboprophylaxis in patients at risk of thrombotic events; and antithrombotic therapies in patients with thrombotic events

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

**X No**

Yes

If yes, please describe:

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and Treatment of VTE in Patients with Cancer (systematic reviews) Baseline risk (systematic review)
------------------	---

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/25/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	8/16/2018 Alexander	On 8/16/2018, Elie Akl confirmed all information in this form.
Yes	7/8/2020 Alexander	On 7/8/2020, Elie Akl confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

**No**

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

**No**

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

**Yes**

If yes, what were those views and where were they made?

Over the past years, I've been involved in the conduct and update of systematic reviews and meta-analyses on "Anticoagulation and cancer". The related publications were published as Cochrane Collaboration products and are available in PubMed.

## Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

**Yes, as described below:**

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

I am an author on six Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000.

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer  
 Elie A Akl , Lara A Kahale , Francesca Sperati , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Maddalena Barba , Elena V Sempos , Paola Muti , Deborah Cook and Holger Schünemann  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: June 2014

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation  
 Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosucio , Maddalena Barba , Francesca Sperati and Holger Schünemann  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: July 2014

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer  
 Elie A Akl , Lara A Kahale , Ignacio Neumann , Maddalena Barba , Francesca Sperati , Irene Terrenato , Paola Muti and Holger Schünemann  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: June 2014

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer



Elie A Akl , Lara A Kahale , Maddalena Barba , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Francesca Sperati , Paola Muti and Holger Schünemann.  
Cochrane Database of Systematic Reviews  
Online Publication Date: July 2014

Anticoagulation for people with cancer and central venous catheters  
Elie A Akl , Elie P Ramly , Lara A Kahale , Victor E D Yosucio , Maddalena Barba , Francesca Sperati , Deborah Cook and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: October 2014

Parenteral anticoagulation in ambulatory patients with cancer  
Elie A Akl , Lara A Kahale , Rami A Ballout , Maddalena Barba , Victor E D Yosucio , Frederiek F van Doormaal , Saskia Middeldorp , Andrew Bryant and Holger Schünemann.  
Cochrane Database of Systematic Reviews  
Online Publication Date: December 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic? No
5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

**No**

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

**Yes**

If yes, please explain:

In terms of impact factor, which translates into financial support from the Italian Ministry of Health to the Regina Elena national Cancer Institute

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

They would enthusiastically support further initiatives.

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

I'm a clinician-scientist. My field is medical oncology.

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

**Yes**

If yes, please explain:

Under appropriate circumstances, I do recommend instrumental and laboratory screening to cancer patients for thrombophilia risk assessment.

### Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

**Yes**

If yes, please describe:

I do expect further research within this same pipeline.

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and treatment of VTE in patients with cancer (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	10/20/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	7/21/2020 Alexander	On 7/21/2020, Maddalena Barba confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

**No**

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

**No**

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

**No**

Yes

If yes, what were those views and where were they made?

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

**No**



Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

**No**

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

**X No**

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

**X No**

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

**I would not receive any support related to the aforementioned.**

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**X No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

**Research fellow**

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

**X No**

Yes

If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

**No**

Yes

If yes, please describe:

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Guideline topic:	Prevention and treatment of VTE in patients with cancer (systematic reviews) Prevention and treatment of VTE in medical patients (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/20/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	8/16/2018 Alexander	On 8/16/2018, Maram Hakoum confirmed all information in this form.
Yes	7/11/2020 Alexander	On 7/11/2020, Maram Hakoum confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No



Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

I am an author on six Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000.

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer

Elie A Akl , Lara A Kahale , Francesca Sperati , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Maddalena Barba , Elena V Sempos , Paola Muti , Deborah Cook and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: June 2014

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation

Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosucio , Maddalena Barba , Francesca Sperati and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: July 2014

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

Elie A Akl , Lara A Kahale , Ignacio Neumann , Maddalena Barba , Francesca Sperati , Irene Terrenato , Paola Muti and Holger Schünemann

Cochrane Database of Systematic Reviews

Online Publication Date: June 2014

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer

Elie A Akl , Lara A Kahale , Maddalena Barba , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Francesca Sperati , Paola Muti and Holger Schünemann.

Cochrane Database of Systematic Reviews

Online Publication Date: July 2014

Anticoagulation for people with cancer and central venous catheters

Elie A Akl , Elie P Ramly , Lara A Kahale , Victor E D Yosucio , Maddalena Barba , Francesca Sperati ,  
Deborah Cook and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: October 2014

Parenteral anticoagulation in ambulatory patients with cancer  
Elie A Akl , Lara A Kahale , Rami A Ballout , Maddalena Barba , Victor E D Yosucio , Frederiek F van  
Doormaal , Saskia Middeldorp , Andrew Bryant and Holger Schünemann.  
Cochrane Database of Systematic Reviews  
Online Publication Date: December 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know  
 No  
 Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know  
 No  
 Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know  
 No  
 Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

Usual support

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

I am a neonatal nurse and clinical epidemiologist.

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and Treatment of VTE in Patients with Cancer (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/14/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	6/12/2020 Alexander	On 6/12/2020, Dr. Kahale confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

## Part D. New Interests

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	<p>Matar CF, <b>Kahale LA</b>, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosuco VED, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA.</p> <p>Anticoagulation for perioperative thromboprophylaxis in people with cancer.</p> <p><b>Cochrane Database of Systematic Reviews</b> 2018, Issue 7. Art. No.: CD009447. DOI: 10.1002/14651858.CD009447.pub3</p> <p><b>Kahale LA</b>, Hakoum MB, Tsolakian IG, Alturki F, Matar CF, Terrenato I, Sperati F, Barba M, Yosuco VED, Schünemann H, Akl EA. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.</p> <p><b>Cochrane Database of Systematic Reviews</b> 2018, Issue 6. Art. No.: CD006650. DOI: 10.1002/14651858.CD006650.pub5</p> <p><b>Kahale LA</b>, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosuco VED,</p>	6/12/2020	Not a COI. This is an update to Part B, Question 3

Company	Description	Disclosure Date	ASH Internal Notes
	<p>Terrenato I, Sperati F, Schünemann H, Akl EA. Anticoagulation for people with cancer and central venous catheters. <b>Cochrane Database of Systematic Reviews</b> 2018, Issue 6. Art. No.: CD006468. DOI: 10.1002/14651858.CD006468.pub6</p> <p>Hakoum MB, <b>Kahale LA</b>, Tsolakian IG, Matar CF, Yosuco VED, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <b>Cochrane Database of Systematic Reviews</b> 2018, Issue 1. Art. No.: CD006649. DOI: 10.1002/14651858.CD006649.pub7.</p> <p><b>Kahale LA</b>, Hakoum MB, Tsolakian IG, Matar CF, Barba M, Yosuco VE, Terrenato I, Sperati F, Schünemann H, Akl EA. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.</p>		

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	<p><b>Cochrane Database of Systematic Reviews</b>                      2017 Dec;                      12:CD006466-.</p> <p>Akl EA, <b>Kahale LA</b>,                      Hakoum MB, Matar CF, Sperati F, Barba M, Yosunico VED, Terrenato I, Synnot A, Schünemann H.                      Parenteral anticoagulation in ambulatory patients with cancer. <b>Cochrane Database of Systematic Reviews</b> 2017, Issue 9. Art. No.:CD006652. DOI: 10.1002/14651858.CD006652.pub5.</p>		





# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic? No, it will not be affected.
5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?
- Don't know
- No
- Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

I will receive the usual support from my primary mentor.

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

I am a PGY1 (Intern) of Internal Medicine at AUBMC (Beirut, Lebanon)

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and treatment of VTE in patients with cancer (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/20/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest.
Yes	6/10/2020 Alexander	On 6/10/2020, Charbal Matar confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--





# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

**No**

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

**No**

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

**No**

Yes

If yes, what were those views and where were they made?

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

**X Yes, as described below:**

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

I am an author on 5 Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000.

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer  
Elie A Akl , Lara A Kahale , Francesca Sperati , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Maddalena Barba , Elena V Sempos , Paola Muti , Deborah Cook and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: June 2014

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation  
Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosuco , Maddalena Barba , Francesca Sperati and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: July 2014

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer  
Elie A Akl , Lara A Kahale , Ignacio Neumann , Maddalena Barba , Francesca Sperati , Irene Terrenato , Paola Muti and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: June 2014

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer  
Elie A Akl , Lara A Kahale , Maddalena Barba , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Francesca Sperati , Paola Muti and Holger Schünemann.  
Cochrane Database of Systematic Reviews  
Online Publication Date: July 2014

Anticoagulation for people with cancer and central venous catheters  
Elie A Akl , Elie P Ramly , Lara A Kahale , Victor E D Yosuco , Maddalena Barba , Francesca Sperati , Deborah Cook and Holger Schünemann

Cochrane Database of Systematic Reviews  
 Online Publication Date: October 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

**No**

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

**X No**

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

**X Don't know**

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

**No additional support**

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

**Statistician**

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

**No**

Yes

If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

**No**

Yes

If yes, please describe:



## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and treatment of VTE in patients with cancer (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/20/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	7/21/2020 Alexander	On 7/21/2020, Francesca Sperati confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

**No**

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

**No**

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

**No**

Yes

If yes, what were those views and where were they made?

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

**X Yes, as described below:**

- Column 1 Name the entity funding the research.
- Column 2 Describe the research project.
- Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
- Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

I am an author on 4 Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000.

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer  
Elie A Akl , Lara A Kahale , Francesca Sperati , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Maddalena Barba , Elena V Sempos , Paola Muti , Deborah Cook and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: June 2014

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation  
Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosunico , Maddalena Barba , Francesca Sperati and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: July 2014

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer  
Elie A Akl , Lara A Kahale , Ignacio Neumann , Maddalena Barba , Francesca Sperati , Irene Terrenato , Paola Muti and Holger Schünemann  
Cochrane Database of Systematic Reviews  
Online Publication Date: June 2014

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer  
Elie A Akl , Lara A Kahale , Maddalena Barba , Ignacio Neumann , Nawman Labedi , Irene Terrenato , Francesca Sperati , Paola Muti and Holger Schünemann.  
Cochrane Database of Systematic Reviews  
Online Publication Date: July 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

**No**

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

**X No**

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

**X Don't know**

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

**No additional support**

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**X No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

**Statistician**

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

**X No**

Yes

If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

**X No**

Yes

If yes, please describe:



## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C)publically available.

Guideline topic:	Prevention and treatment of VTE in patients with cancer (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/20/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	7/21/2020 Alexander	On 7/21/2020, Irene Terrenato confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.



## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

## Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

## Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

## Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

no

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

No support

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

student

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes



If yes, please explain:

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

# Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	VTE in patients with cancer (systematic reviews) Baseline risk (systematic reviews)
------------------	--

<i>Approved to participate?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	8/9/2018 Alexander	No material conflicts of interest.
Yes	7/8/2020 Alexander	On 7/8/2020, Ibrahim Tsolakian confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



# ASH Guidelines Researcher Declaration of Interests Form

## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

**No**

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

**No**

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

## Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 5.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

**X No**

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

**No**

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

Venous thromboembolism

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic.

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

**No**

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

**Yes**

If yes, what were those views and where were they made?

Part of previous Cochrane reviews on anticoagulation in cancer patients.

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

**X Yes, as described below:**

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

I am an author on 3 Cochrane systematic reviews on the topic of anticoagulation for venous thromboembolic disease in patients with cancer. All the reviews were funded by the 2013 National Institute for Health Research Cochrane Review Incentive Scheme; funding duration was 1/1/13-12/31/13; funding amount was £5,000.

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation  
 Elie A Akl , Lara Kahale , Irene Terrenato , Ignacio Neumann , Victor E D Yosuico , Maddalena Barba , Francesca Sperati and Holger Schünemann  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: July 2014

Anticoagulation for people with cancer and central venous catheters  
 Elie A Akl , Elie P Ramly , Lara A Kahale , Victor E D Yosuico , Maddalena Barba , Francesca Sperati , Deborah Cook and Holger Schünemann  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: October 2014

Parenteral anticoagulation in ambulatory patients with cancer  
 Elie A Akl , Lara A Kahale , Rami A Ballout , Maddalena Barba , Victor E D Yosuico , Frederiek F van Doormaal , Saskia Middeldorp , Andrew Bryant and Holger Schünemann.  
 Cochrane Database of Systematic Reviews  
 Online Publication Date: December 2014

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

**No**

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

**No**

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

Favorably.

## Advocacy and Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

**No**

Yes. Name of organization(s): \_\_\_\_

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?



Don't know or not applicable

No

Yes

If yes, please explain:

## Professional Specialty

9. What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?

Clinician in private practice. Hematology and Medical Oncology.

10. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

**Yes**

If yes, please explain:

I have cancer and hematology patients that I prescribe anticoagulation treatments.

## Expected Interests

11. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

**No**

Yes

If yes, please describe:

## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Guideline topic:	Prevention and Treatment of VTE in Patients with Cancer
------------------	---

<i>Approved to participate?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	10/25/16 Alexander; 10/26/16 Kunkle	No material conflicts of interest
Yes	6/10/2020 Alexander	On 6/10/2020, Victor Yosuico confirmed all information in this form.

Summarize all current material interests in affected companies described above:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--